Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 9/20 | 0.75 |
| ▸ | GSK3A | P49840 | 2/20 | 0.69 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.69 |
| ▸ | PNP | P00491 | 1/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | KRAS | P01116 | 5/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219707 | 0.87 | GSK3A (0.80) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5999289 | 0.86 | HINT1 (0.55) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL439016 | 0.85 | HINT1 (0.78) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9545419 | 0.85 | POLB (0.60) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL7915394 | 0.85 | HINT1 (0.71) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL217117 | 0.84 | HINT1 (0.80) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295421 | 0.83 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295418 | 0.83 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL29060313 | 0.83 | HINT1 (0.69) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL1533274 | 0.82 | HINT1 (0.73) | HINT1GSK3ARPS6KA3MAPK14PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653254-B2 | Process for producing nucleoside | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120071646-A1 | PROCESS FOR PRODUCING NUCLEOSIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071646-A1 | PROCESS FOR PRODUCING NUCLEOSIDE | NUDT1, PNP, HPRT1 | HINT1 42/4885GSK3A 3961/4885RPS6KA3 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.